Cargando…

Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty—results from a randomized placebo-controlled clinical trial

SUMMARY: We investigated whether the drug denosumab modulates the inflammatory response after total hip arthroplasty in a randomized controlled trial. Significantly increased expression of RANKL was found in patients treated with denosumab. This could provide an explanation for the rebound effect wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sköld, C., Kultima, K., Freyhult, E., Larsson, A., Gordh, T., Hailer, N.P., Mallmin, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463208/ https://www.ncbi.nlm.nih.gov/pubmed/35608639 http://dx.doi.org/10.1007/s00198-022-06423-w

Ejemplares similares

Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters
por: Abe, Ichiro, et al.
Publicado: (2019)

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review
por: de Oliveira, Camila-Carvalho, et al.
Publicado: (2016)

Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial
por: KIRITOPOULOS, Demostenis, et al.
Publicado: (2022)

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014)

Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation
por: Fang, Lei, et al.
Publicado: (2008)

Effect of Cornus Officinalis on Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL)-induced Osteoclast Differentiation
por: Kim, Jung Young, et al.
Publicado: (2012)

Evaluation of the Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Expression in Osteosarcoma and Its Association with the Clinicopathological Data
por: Chua, Hui Heng, et al.
Publicado: (2021)

TNFα Causes a Shift in Gene Expression of TNFRSF1A and TNFRSF1B Isoforms
por: Perik-Zavodskaia, Olga, et al.
Publicado: (2023)

Receptor activator of NF-kappaB ligand (RANKL) and CD 31 expressions in chronic periodontitis patients before and after surgery
por: Friedmann, Anton, et al.
Publicado: (2014)

Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor
por: Coleman, RE
Publicado: (2009)

Cerebrospinal Fluid in Classical Trigeminal Neuralgia: An Exploratory Study on Candidate Biomarkers
por: Svedung Wettervik, Teodor, et al.
Publicado: (2022)

Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis
por: Boman, Antonia, et al.
Publicado: (2017)

A novel TNFRSF1A mutation associated with TNF-receptor-associated periodic syndrome and its metabolic signature
por: Steiner, Joachim D, et al.
Publicado: (2023)

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
por: Zhang, Ning, et al.
Publicado: (2020)

α-Tocopheryl Succinate Inhibits Osteoclast Formation by Suppressing Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL) Expression and Bone Resorption
por: Kim, Ha-Neui, et al.
Publicado: (2012)

Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review
por: Wang, Daoxi, et al.
Publicado: (2023)

Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis
por: Lee, Eun Young, et al.
Publicado: (2011)

TNFRSF1B and TNF Variants Are Associated With Differences in Levels of Soluble Tumor Necrosis Factor Receptors in Patients With Severe COVID-19( )
por: Fricke-Galindo, Ingrid, et al.
Publicado: (2022)

Association of TNF-α, TNFRSF1A and TNFRSF1B Gene Polymorphisms with the Risk of Sporadic Breast Cancer in Northeast Chinese Han Women
por: Xu, Fengyan, et al.
Publicado: (2014)

CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis
por: Tsushima, Hidetoshi, et al.
Publicado: (2015)

Eleutherococcus sessiliflorus Inhibits Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Induced Bone Loss
por: Han, Sang-Yong, et al.
Publicado: (2021)

Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss
por: Han, Sang-Yong, et al.
Publicado: (2021)

Effects of Lactobacillus reuteri MG5346 on Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL)-Induced Osteoclastogenesis and Ligature-Induced Experimental Periodontitis Rats
por: Jeong, Yu-Jin, et al.
Publicado: (2023)

Pharmacological profiles of opioid ligands at Kappa opioid receptors
por: Gharagozlou, Parham, et al.
Publicado: (2006)

Identification of novel ligands interacting with kappa opioid receptors
por: Spetea, Mariana, et al.
Publicado: (2011)

Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands
por: Sturaro, Chiara, et al.
Publicado: (2022)

A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report
por: Horikoshi, Keisuke, et al.
Publicado: (2020)

Polymorphisms in TNF Receptor Superfamily 1B (TNFRSF1B:rs3397) are Linked to Mycobacterium avium paratuberculosis Infection and Osteoporosis in Rheumatoid Arthritis
por: Naser, Amna, et al.
Publicado: (2019)

Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals
por: Lin, Sheng-Chieh, et al.
Publicado: (2023)

Association of TNF-857C>T, TNFRSF1A36A>G, and TNFRSF1B676T>G Polymorphisms with Ischemic Stroke in a Greek Population
por: Markoula, Sofia, et al.
Publicado: (2011)

In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
por: Melagraki, Georgia, et al.
Publicado: (2018)

Do dual-mobility cups cemented into porous tantalum shells reduce the risk of dislocation after revision surgery?: A retrospective cohort study on 184 patients
por: Brüggemann, Anders, et al.
Publicado: (2018)

Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
por: Dardari, Dured, et al.
Publicado: (2022)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Challenges in long-term control of hypercalcaemia with denosumab after haematopoietic stem cell transplantation for TNFRSF11A osteoclast-poor autosomal recessive osteopetrosis
por: Taylor-Miller, Tashunka, et al.
Publicado: (2020)

Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities
por: Schmidhammer, Helmut, et al.
Publicado: (2020)

Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease
por: Qasem, Ahmad, et al.
Publicado: (2019)

Distribution of five clinically important neuroglial proteins in the human brain
por: Sjölin, Karl, et al.
Publicado: (2022)

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab
por: Regev, Ravit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cv8s44kkdgegkfapno5e2h5mom